| [1] |
Tokarev AA, Butylin AA, Ataullakhanov FI. Platelet adhesion from shear blood flow is controlled by near-wall rebounding collisions with erythrocytes[J]. Biophys J, 2011, 100(4): 799-808. DOI: 10.1016/j.bpj.2010.12.3740.
|
| [2] |
Chang R, Cardenas JC, Wade CE, et al. Advances in the understanding of trauma-induced coagulopathy[J]. Blood, 2016, 128(8): 1043-1049. DOI: 10.1182/blood-2016-01-636423.
|
| [3] |
Gavins FN, Russell J, Senchenkova EL, et al. Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-s[J]. Blood, 2011, 117(15): 4125-4133. DOI: 10.1182/blood-2010-08-301366.
|
| [4] |
Fan X, Yu Z, Liu J, et al. Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy[J]. Stroke, 2010, 41(10 Suppl): S54-S58. DOI: 10.1161/strokeaha.110.596106.
|
| [5] |
Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation[J]. Blood, 2019, 133(6): 511-520. DOI: 10.1182/blood-2018-07-818211.
|
| [6] |
|
| [7] |
Todd J, Bharadwaj VN, Nellenbach K, et al. Platelet-like particles reduce coagulopathy-related and neuroinflammatory pathologies post-experimental traumatic brain injury[J]. J Biomed Mater Res B Appl Biomater, 2021, 109(12): 2268-2278. DOI: 10.1002/jbm.b.34888.
|
| [8] |
Rimaitis M, Cechanovičiūtė V, Bilskienė D, et al. Dynamic changes of hemostasis in patients with traumatic brain injury undergoing craniotomy: association with in-hospital mortality[J]. Neurocrit Care, 2023, 38(3): 714-725. DOI: 10.1007/s12028-022-01639-4.
|
| [9] |
Dean T, Mendiola AS, Yan Z, et al. Fibrin promotes oxidative stress and neuronal loss in traumatic brain injury via innate immune activation[J]. J Neuroinflammation, 2024, 21(1): 94. DOI: 10.1186/s12974-024-03092-w.
|
| [10] |
Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors[J]. Semin Thromb Hemost, 2014, 40(3): 325-331. DOI: 10.1055/s-0034-1370791.
|
| [11] |
Magnus N, D'Asti E, Garnier D, et al. Brain neoplasms and coagulation[J]. Semin Thromb Hemost, 2013, 39(8): 881-895. DOI: 10.1055/s-0033-1357483.
|
| [12] |
Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2015, 46(7): 2032-2060. DOI: 10.1161/str.0000000000000069.
|
| [13] |
Gorzelak-Pabiś P, Pawlos A, Broncel M, et al. Expression of anti and pro-inflammatory genes in human endothelial cells activated by 25-hydroxycholesterol: a comparison of rivaroxaban and dabigatran[J]. Clin Exp Pharmacol Physiol, 2022, 49(8): 805-812. DOI: 10.1111/1440-1681.13668.
|
| [14] |
Yang K, Zeng L, Ge A, et al. A systematic review of the research progress of non-coding RNA in neuroinflammation and immune regulation in cerebral infarction/ischemia-reperfusion injury[J]. Front Immunol, 2022, 13: 930171. DOI: 10.3389/fimmu.2022.930171.
|
| [15] |
Dziedzic T. Systemic inflammation as a therapeutic target in acute ischemic stroke[J]. Expert Rev Neurother, 2015, 15(5): 523-531. DOI: 10.1586/14737175.2015.1035712.
|
| [16] |
Maegele M, Schöchl H, Menovsky T, et al. Coagulopathy and haemorrhagic progression in traumatic brain injury: advances in mechanisms, diagnosis, and management[J]. Lancet Neurol, 2017, 16(8): 630-647. DOI: 10.1016/s1474-4422(17)30197-7.
|
| [17] |
Thiebaut AM, Gauberti M, Ali C, et al. The role of plasminogen activators in stroke treatment: fibrinolysis and beyond[J]. Lancet Neurol, 2018, 17(12): 1121-1132. DOI: 10.1016/s1474-4422(18)30323-5.
|
| [18] |
Jin R, Xiao AY, Li J, et al. PI3Kγ (Phosphoinositide 3-Kinase-γ) inhibition attenuates tissue-type plasminogen activator-induced brain hemorrhage and improves microvascular patency after embolic stroke[J]. Hypertension, 2019, 73(1): 206-216. DOI: 10.1161/hypertensionaha.118.12001.
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
Ariëns RA, de Lange M, Snieder H, et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state[J]. Lancet, 2002, 359(9307): 667-671. DOI: 10.1016/s0140-6736(02)07813-3.
|
| [24] |
Singh S, Kumar P, Padwad YS, et al. Targeting fibrinolytic inhibition for venous thromboembolism treatment: overview of an emerging therapeutic approach[J]. Circulation, 2024, 150(11): 884-898. DOI: 10.1161/circulationaha.124.069728.
|
| [25] |
Abdul S, Leebeek FW, Rijken DC, et al. Natural heterogeneity of α2-antiplasmin: functional and clinical consequences[J]. Blood, 2016, 127(5): 538-545. DOI: 10.1182/blood-2015-09-670117.
|
| [26] |
Nekludov M, Antovic J, Bredbacka S, et al. Coagulation abnormalities associated with severe isolated traumatic brain injury: cerebral arterio-venous differences in coagulation and inflammatory markers[J]. J Neurotrauma, 2007, 24(1): 174-180. DOI: 10.1089/neu.2006.0173.
|
| [27] |
Rausa E, Kelly ME, Asti E, et al. Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: systematic review and meta-analysis of randomized clinical trials[J]. Surgery, 2018, 164(6): 1234-1240. DOI: 10.1016/j.surg.2018.05.028.
|
| [28] |
Lee SY, Niikura T, Iwakura T, et al. Thrombin-antithrombin III complex tests[J]. J Orthop Surg (Hong Kong), 2017, 25(1): 170840616684501. DOI: 10.1177/0170840616684501.
|
| [29] |
Liu Y, Ma J, Shi Q, et al. Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment[J]. Health Sci Rep, 2021, 4(1): e218. DOI: 10.1002/hsr2.218.
|
| [30] |
Zunker P, Schick A, Padró T, et al. Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology[J]. Neurol Res, 1999, 21(8): 727-732. DOI: 10.1080/01616412.1999.11741005.
|
| [31] |
Winter MP, Kleber ME, Koller L, et al. Prognostic significance of tPA/PAI-1 complex in patients with heart failure and preserved ejection fraction[J]. Thromb Haemost, 2017, 117(3): 471-478. DOI: 10.1160/th16-08-0600.
|
| [32] |
Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta[J]. J Cell Biol, 1985, 101(2): 363-371. DOI: 10.1083/jcb.101.2.363.
|
| [33] |
Zhang X, Hu Y, Hong M, et al. Plasma thrombomodulin, fibrinogen, and activity of tissue factor as risk factors for acute cerebral infarction[J]. Am J Clin Pathol, 2007, 128(2): 287-292. DOI: 10.1309/hb6ab1yr4dqut5au.
|
| [34] |
Koyama K, Madoiwa S, Nunomiya S, et al. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study[J]. Crit Care, 2014, 18(1): R13. DOI: 10.1186/cc13190.
|
| [35] |
Lundbech M, Krag AE, Christensen TD, et al. Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients[J]. Thromb Res, 2020, 186: 80-85. DOI: 10.1016/j.thromres.2019.12.018.
|
| [36] |
Pottier P, Fouassier M, Hardouin JB, et al. D-dimers, thrombin-antithrombin complexes, and risk factors for thromboembolism in hospitalized patient[J]. Clin Appl Thromb Hemost, 2009, 15(6): 666-675. DOI: 10.1177/1076029608321436.
|
| [37] |
Yamada S, Asakura H. Therapeutic strategies for disseminated intravascular coagulation associated with aortic aneurysm[J]. Int J Mol Sci, 2022, 23(3): 1296. DOI: 10.3390/ijms23031296.
|
| [38] |
Hilmi IA, Planinsic RM. Live liver donors: are they at a higher risk for post-operative thrombotic complications?[J]. World J Transplant, 2012, 2(1): 1-4. DOI: 10.5500/wjt.v2.i1.1.
|
| [39] |
Guo X, Tao H, Li D, et al. The α2-plasmin inhibitor-plasmin complex is a potential biomarker of venous thromboembolism in orthopedic trauma patients[J]. Clin Lab, 2021, 67(4): 856. DOI: 10.7754/Clin.Lab.2020.200856.
|
| [40] |
Nielsen VG, Matika RW, Ley ML, et al. Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer[J]. Blood Coagul Fibrinolysis, 2014, 25(3): 248-253. DOI: 10.1097/mbc.0000000000000040.
|
| [41] |
Yagi K, Tao Y, Hara K, et al. Increased plasma plasmin-α2-plasmin inhibitor complex levels correlate with postoperative rebleeding after endoscopic surgery for spontaneous intracerebral hemorrhage[J]. Acta Neurochir (Wien), 2020, 162(12): 3129-3136. DOI: 10.1007/s00701-019-04154-2.
|
| [42] |
Johansson L, Jansson JH, Boman K, et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke[J]. Stroke, 2000, 31(1): 26-32. DOI: 10.1161/01.str.31.1.26.
|
| [43] |
Holmes C, Butchart J. Systemic inflammation and Alzheimer's disease[J]. Biochem Soc Trans, 2011, 39(4): 898-901. DOI: 10.1042/bst0390898.
|
| [44] |
Hino H, Akiyama H, Iseki E, et al. Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues[J]. Neurosci Lett, 2001, 297(2): 105-108. DOI: 10.1016/s0304-3940(00)01679-7.
|
| [45] |
Pletsch-Borba L, Grafetstätter M, Hüsing A, et al. Vascular injury biomarkers and stroke risk: a population-based study[J]. Neurology, 2020, 94(22): e2337-e2345. DOI: 10.1212/wnl.0000000000009391.
|
| [46] |
Olivot JM, Labreuche J, Aiach M, et al. Soluble thrombomodulin and brain infarction: case-control and prospective study[J]. Stroke, 2004, 35(8): 1946-1951. DOI: 10.1161/01.STR.0000133340.37712.9b.
|
| [47] |
Bai H, Shen L, Zhang H, et al. Clinical value of TAT, PIC and t-PAIC as predictive markers for severe sepsis in pediatric patients[J]. Front Pediatr, 2024, 121336583. DOI: 10.3389/fped.2024.1336583.
|
| [48] |
Abdelmaguid A, Roberts LN, Tugores L, et al. Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease[J]. J Thromb Haemost, 2022, 20(4): 845-856. DOI: 10.1111/jth.15653.
|